Novo Nordisk Terminates Korro Bio Collaboration, Effective February 2027
KRRO has more than doubled off its 52-week low of $5.204.
Summary
Novo Nordisk is terminating its RNA-editing collaboration with Korro Bio effective February 1, 2027, ending a deal that had been paused since November 2025 and had produced no milestone payments. Korro reported $124.8 million in cash with runway into the second half of 2028.
Updates
· Dow Jones Newswires — Korro Bio shares fell 11% to $14.88 after Novo Nordisk's termination notice; Korro was eligible for up to $530 million in milestones under the 2024 pact.
Key Events · M&A and Partnerships · KRRO
-
Novo Nordisk Terminates Collaboration
On November 3, 2026, Korro received written notice that Novo Nordisk had elected to terminate for convenience the September 13, 2024 research collaboration and license agreement, effective February 1, 2027.
-
No Milestones Earned, No Penalties
Korro received a $10.0 million upfront payment and R&D cost reimbursement, all non-refundable, and earned no milestone payments. No early termination penalties apply, and Novo Nordisk will reimburse additional third-party wind-down and non-cancellable committed costs.
-
Deal Was Already Paused
The parties amended the agreement effective November 11, 2025 to pause it for 12 months and suspend all R&D; Korro completed its wind-down in 2025, and Novo Nordisk neither nominated a second target nor substituted the collaboration target.
-
Cash Runway Into 2H 2028
Cash, cash equivalents and marketable securities stood at $124.8 million as of September 30, 2026, versus $85.2 million at December 31, 2025, funding operations into the second half of 2028.
Analysis · KRRO · Life Sciences
Korro is losing its only partnered program: Novo Nordisk is walking away from the September 2024 cardiometabolic RNA-editing deal, with the license ending February 1, 2027. The financial hit is limited, since the deal had been paused since November 2025 and no milestones were ever earned — the $10.0 million upfront is non-refundable and no termination penalties apply. The strategic reset is what matters. Korro is now a fully self-funded story built on KRRO-121 and KRRO-111, and its $124.8 million in cash carries it into the second half of 2028, past the expected interim ANCHOR data in 2H 2027. With a large-pharma partner gone, external validation and any future milestone or royalty stream go with it, leaving the equity to ride entirely on the internal pipeline and on management's ability to raise capital later.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRRO was trading at $16.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $244.7M. The 52-week trading range was $5.20 to $38.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.